Nucleical Molecular Visibility: Plugin for Oncology Screening

In the increasingly complex diagnosis and treatment of tumours, early detection and precision diagnosis have been important challenges in the field of medicine. As a “black technology” of modern medicine, the nucleus of nuclear medicine is re-energizing tumour screening with its unique advantage. What’s a nuclear-medicine molecule? The visible image of the nuclear medicine molecule is an advanced imaging technology that combines radionuclide and molecular probe technology. In short, it “traces” specific molecular biomarkers in the parts of the stove by injecting a specific radioactive substance, and then captures these radioactive signals with nuclear medical equipment (e.g. PET/CT) to produce clear images. The core of this technology is the “molecule probe” – it’s like a key specifically designed for tumours that identifies molecular characteristics specific to tumour cells. The precision of this molecular level makes the nucleo-medical molecule more visible not only in the “form” of the tumor, but also in the “temporal” of the tumor. 1. Early detection of tumour nuclei can detect early pathologies that have not yet resulted in a significant structural change in anatomy. For example, the use of the 18F-FDG (fluorinated deoxygent glucose) PET/CT visuals can detect tumour cells that are metabolically active and identify problems one step earlier than traditional means of image (e.g. CT, MRI). 2. The tumour stratification and positioning of different types of tumours often have unique molecular markers. Prostate cancer, for example, can be precisely positioned through PSMA (prostate amphibious membrane antigen) PET graphics, while lung cancer patients can use EGFR (surfactor growth factor receptor) for the visualization and rapid determination of tumour types. 3. Assessing the effects of treatment in the course of treatment can dynamically observe metabolic or molecular changes in tumours. For example, after chemotherapy or target treatment, a visual assessment of whether tumours are decreasing or not active can be visualized, providing a scientific basis for doctors to adjust treatment programmes. 4. The most serious concern for cancer patients is relapse and transfer. The nucleophysics can help doctors quickly to detect re-emergences and even track the transfer of pathologies from afar to gain more treatment opportunities for patients. The unique advantage of the molecular profile of nuclear medicine is high sensitivity and specificity: it detects minor pathologies at the molecular or metabolic level and avoids leakage. Non-intrusive: it has little trauma to patients compared to the traditional method of active identification. Full body image: A single scan will allow an assessment of the distribution of the entire body, especially in the search for multiple cases. Case sharing: An early “invisible” lung cancer patient, a 50-year-old male, came to hospital for long coughing. No apparent anomalies were observed in the general chest, but after an 18F-FDG PET/CT exercise, the doctor found that there was a small problem of metabolic abnormality on the top of his right lung. Further examination confirmed early lung cancer. Because of the timeliness of the discovery, he had to be fully cured by a micro-surgery. With the progressive development of nuclear medicine molecular imaging, more new molecular probes of a high heterogeneity will be developed, providing more possibilities for the screening of different types of tumours. Nuclear medicine is not only a diagnostic discipline, but also an important cornerstone of future precision medicine. Early detection and precision diagnosis of tumours may determine the continuation of a life. The image of nuclear medicine molecules is like a “twice of eyes” in the field of medicine, which provides doctors with the ability to spy on the depths of the disease. In the future, let us look forward to this technology going into more hospitals to help more patients get the light of hope for early diagnosis.